Aquestive therapeutics announces positive epiphast ii trial data for aqst-109 when compared to epipen®

Warren, n.j., sept. 27, 2022 (globe newswire) -- aquestive therapeutics, inc. (nasdaq: aqst), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today announced positive topline results from the epiphast ii trial for its aqst-109 epinephrine sublingual film.
AQST Ratings Summary
AQST Quant Ranking